Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
Inhibition of intestinal P-glycoprotein might enhance the absorption of orally administered P-glycoprotein substrate drugs. We show here a 10-fold increased oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. These results encourage further research on the development of a clinically useful oral formulation of paclitaxel.
van Asperen
J
J
Department of Clinical Chemistry, The Netherlands Cancer Institute, Amsterdam.
van Tellingen
O
O
Sparreboom
A
A
Schinkel
A H
AH
Borst
P
P
Nooijen
W J
WJ
Beijnen
J H
JH
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors*; D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D003524:Cyclosporins / Q000008:administration & dosage*; D004338:Drug Combinations; D005260:Female; D051379:Mice; D008815:Mice, Inbred Strains; D017239:Paclitaxel / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D013997:Time Factors
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D003524:Cyclosporins; D004338:Drug Combinations; D017239:Paclitaxel; C070272:valspodar